Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 12/20 | 0.69 |
| ▸ | EPAS1 | Q99814 | 17/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | ARNT | P27540 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18078040 | 0.84 | VEGFA (0.72) | VEGFAEPAS1CYP2C9ARNTCYP2C19 | |
| SCHEMBL16560925 | 0.82 | VEGFA (1.00) | VEGFAEPAS1CYP2C9ARNTCYP2C19 | |
| SCHEMBL21005089 | 0.82 | VEGFA (1.00) | VEGFAEPAS1CYP2C9ARNTCYP2C19 | |
| SCHEMBL19870704 | 0.82 | EPAS1 (0.61) | VEGFAEPAS1 | |
| SCHEMBL18078039 | 0.82 | EPAS1 (0.71) | VEGFAEPAS1CYP2C9ARNTCYP2C19 | |
| SCHEMBL18688646 | 0.81 | EPAS1 (0.61) | VEGFAEPAS1 | |
| SCHEMBL18078026 | 0.81 | EPAS1 (0.58) | VEGFAEPAS1 | |
| SCHEMBL18047839 | 0.81 | EPAS1 (0.61) | VEGFAEPAS1 | |
| SCHEMBL18078060 | 0.80 | VEGFA (0.69) | VEGFAEPAS1CYP2C9ARNTCYP2C19 | |
| SCHEMBL19865243 | 0.80 | VEGFA (0.49) | VEGFAEPAS1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148413-A1 | SUBSTITUTED PYRIDINES AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148413-A1 | SUBSTITUTED PYRIDINES AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | VEGFA 174/4885EPAS1 8/4885CYP2C9 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.